Eleven patients with chronic inflammatory arthritides and haemoglobin concentrations less than 105 g/l with symptoms from their anaemia were treated with a dose of 250 IU/kg/week of recombinant human erythropoietin for six weeks. The treatment was given as subcutaneous injections five days a week. All patients had active inflammatory disease. Nine patients responded to treatment with an increase in haemoglobin of more than 15 g/l. The mean (SD) haemoglobin concentration increased from 93-0 (8.0) g/l before treatment to 115-0 (12-0) g/l after six weeks. There was no correlation between the initial serum concentration of erythropoietin and the response. It was concluded that anaemia in chronic inflammatory arthritides responds to treatment with subcutaneous injections of recombinant human erythropoietin.
Chronic inflammatory disease is often associated with a relatively moderate degree of anaemia.`- 3 The aetiology of this anaemia in chronic inflammation appears to be multifactorial and is a matter of controversy. A shortened erythrocyte lifespan is accepted by most workers, but seems to be of quantitatively minor importance. 4 5 A blockage in the release of iron from the reticuloendothelial cells to the erythron has been advocated by some workers6 7 but studies have not been able to support this.8 A reduction in erythrocyte production is thought to be the most important cause. Some studies of patients with rheumatoid arthritis (RA) and anaemia have shown a blunted erythropoietin response, " whereas we and others have shown appropriate serum concentrations of erythropoietin. 12-14 Although patients with RA and anaemia have increased concentrations of serum erythropoietin, the anaemia is not corrected. Erythropoiesis must therefore be inhibited in some way. Patients with renal insufficiency as a group have a markedly blunted erythropoietin response to anaemia. Most, however, have serum erythropoietin concentrations above the reference range. They are not able to correct their anaemia, however, unlike the situation if uraemia is corrected after renal transplantation, when the haemoglobin levels are corrected even if the serum erythropoietin level is the same as before the transplantation. Anaemia of renal insufficiency must therefore be caused by some kind of inhibition of erythropoiesis and maintained by uraemia and a relative lack of erythropoietin. As these patients respond to treatment with erythropoietin' it seemed logical to try to overcome the inhibition of erythropoiesis in chronic inflammation by treatment with exogenous recombinant erythropoietin. The clinical use of recombinant human erythropoietin for anaemic patients with RA has been reported. '6'9 The aim of this study was to evaluate the effect of subcutaneously administered recombinant human erythropoietin in patients with chronic inflammatory arthritides who were anaemic despite treatment with disease modifying drugs.
Patients and methods

PATIENTS
Eleven patients, eight women and three men, with stable inflammatory arthritides and with subjective symptoms of anaemia (haemoglobin <105 g/l) were included in the study. Ten patients, eight women and two men, fulfilled the criteria of the American Rheumatism Association20 for classical RA and one 47 year old man had ankylosing spondylitis according to the New York criteria of the American Rheumatism Association."2 The mean age of the patients was 57 years (range 21-79) and the mean disease duration was 18 years (range 3-33).
Seven patients were treated with disease modifying drugs, seven with low dose corticosteroids, and nine patients were receiving nonsteroidal anti-inflammatory drugs (NSAIDs) ( 
Serum erythropoietin was measured before the start of treatment, weekly during the treatment period, and every other week during the following six weeks after discontinuing treatment with recombinant human erythropoietin. Serum erythropoietin was measured using a previously reported radioimmunoassay method. 25 The detection limit is 0-5 IU/1, and the mean erythropoietin level in normal subjects is 6-7 IU/l (reference range 3-3-13-5 IU/1).
Statistics
Student's t test was used for statistical evaluation of the arithmetic data and the one factorial ANOVA repeated measures test was used to evaluate repeated measurements. Linear correlation analysis of data was used as indicated.
Results
The mean (SD) haemoglobin concentration for the whole group was 93-1 (8-4) g/l before treatment and 1 16-3 (10c1) g/l after five weeks of treatment with recombinant human erythropoietin (p<0-001). The mean (SD) packed cell volume increased during this period from 0-29 (0-028) to 0-36 (0-021) (p<0-001), and the reticulocyte count increased significantly (p<0O05) (fig 1) . Nine of the 11 patients responded to treatment with an increase in haemoglobin of more than 15 g/l, and in four patients the recombinant human erythropoietin dose was reduced according to the treatment schedule. The reduction in the recombinant human erythropoietin dose was associated with a minor decrease of the haemoglobin concentration and reticulocyte count (fig 1) . The two patients with renal insufficiency due to secondary amyloidosis responded, despite active inflammation; haemoglobin increased from 98 to 130 and from 75 to 117 g/l respectively (fig 2) . The patients' need of daily rest decreased 41 volumes were still signi-slightly (p<005) during treatment with )efore treatment (p<000l recombinant human erythropoietin by an -ly). There were significant average of 42 minutes or from 1-8 (1 0) (range reticulocyte counts and 0-3) hours to l-1 (0-9) (0-3) hours. Furthermore, iowever, but no significant there was a significant improvement in the oglobin levels (fig 1) . The patients' subjective general condition (p<001), I to the pretreatment level graded on a five grade visual analogue scale (fig 3) . No significant from 3-0 (13) (range 2-5) to 2-0 (15) (1-5).
ved in the mean corpusEight patients had initial serum ferritin concorpuscular haemoglobin, centrations of less than 250 [tg/l and were emoglobin concentration, treated by mouth with iron (100 mg/day). Two erritin, nor serum trans-of these eight patients were non-responders. r the recombinant human ient period in responders serum concentration of re treatment was 1-43). Four 27 Our patient group is too limited to evaluate whether or not the initial serum erythropoietin level has any effect on the response to recombinant human erythropoietin. We found no correlation between the initial serum erythropoietin levels and the relative increase in haemoglobin during recombinant human erythropoietin treatment. The two patients with renal and inflammatory anaemia showed the most dramatic response, indicating that recombinant human erythropoietin treatment is effective in this mixed type of anaemia despite active inflammation.
The fact that serum ferritin did not change significantly during the study indicates that the amount of iron that was absorbed was used for haemoglobin production.
In previous reports, no follow up periods have been included, but Means et al '7 and Takashina et al ' reported a decrease in haemoglobin or packed cell volume after discontinuing recombinant human erythropoietin treatment. In our study, the haemoglobin response lasted several weeks after stopping recombinant human erythropoietin treatment, though the reticulocyte count decreased significantly ( fig 1) . This finding indicates a normal erythrocyte lifespan despite inflammation; increased haemolysis seems to be of minor importance in the aetiology of anaemia in chronic inflammation. At the end of the treatment period, the mean (SD) haemoglobin level was 114-7 (119) g/l, and at the six week follow up the mean (SD) haemoglobin was 106-6 (13-2), still significantly higher (p<0-01) than before treatment. Thus anaemia in RA may be treated with intermittent periods of recombinant human erythropoietin injections. No significant difference was observed in disease activity or functional capacity before and after recombinant human erythropoietin treatment, but the need for daily rest decreased and the patients' subjective estimation of their general condition improved significantly during the study. Four of the responders have chosen to restart treatment with recombinant human erythropoietin.
In conclusion, we have found that patients with anaemia due to chronic inflammatory arthritides respond to treatment with moderate doses of subcutaneous recombinant human erythropoietin and that the treatment is safe. Many patients are capable of giving the subcutaneous injections themselves.
